| 1.67 -0.01 (-0.6%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.28 | 1-year : | 2.53 |
| Resists | First : | 1.95 | Second : | 2.17 |
| Pivot price | 1.75  |
|||
| Supports | First : | 1.61 | Second : | 1.33 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 1.8 |
| MA(100) : | 2.04  |
MA(250) : | 1.82 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 8 |
| RSI | RSI(14): 42.2 |
|||
| 52-week | High : | 3.09 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ COCP ] has closed above bottom band by 27.4%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.72 - 1.73 | 1.73 - 1.74 |
| Low: | 1.6 - 1.61 | 1.61 - 1.62 |
| Close: | 1.65 - 1.67 | 1.67 - 1.68 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Thu, 22 Aug 2024
Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Wed, 14 Aug 2024
COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024 - MSN
Tue, 19 Mar 2024
Cocrystal Pharma advances with FDA feedback on flu treatment By Investing.com - Investing.com Canada
Mon, 10 Apr 2023
Penny Stocks To Buy Now? 4 Under $3 To Watch This Week - Penny Stocks
Tue, 04 May 2021
Reddit Penny Stocks Soar as DogeCoin Hits New All-Time Highs - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 30 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 63 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.71 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.1 % |
| Return on Equity (ttm) | -68.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.96 |
| PEG Ratio | 0 |
| Price to Book value | 0.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|